Combinations of drugs in the treatment of obesity

Pharmaceuticals

Volumn 3, Issue 8, 2010, Pages 2398-2415

  Halpern, Bruno ^a   Oliveira, Eduardo S L ^a   Faria, André M ^a   Halpern, Alfredo ^a   de Melo, Maria Edna ^a   Cercato, Cintia ^a   Mancini, Marcio C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

5 hydroxytryptophan; Antidepressants; Bupropion; Caffeine; Carbidopa; Drug combination; Ephedrine; Fenfluramine; Glucagon like peptide 1; Leptin; Metformin; Metreleptin; Naltrexone; Noradrenergic drugs; Orlistat; Peptide YY; Phentermine; Pramlintide; Sibutramine; Topiramate; Zonisamide

Indexed keywords

5 HYDROXYTRYPTOPHAN; ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMFEPRAMONE; AMYLIN; ANTIDEPRESSANT AGENT; ANTIOBESITY AGENT; CAFFEINE; CARBIDOPA; CONTRAVE; DEXFENFLURAMINE; EMPATIC; EPHEDRINE; EXENDIN 4; FENFLURAMINE; GLUCAGON LIKE PEPTIDE 1; LEPTIN; LIRAGLUTIDE; METFORMIN; METRELEPTIN; NALTREXONE; PEPTIDE YY [3-36]; PHENTERMINE; PLACEBO; PRAMLINTIDE; QNEXA; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNCLASSIFIED DRUG; ZONISAMIDE;

ANXIETY; ARTICLE; BINGE EATING DISORDER; BLOOD PRESSURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONCENTRATION LOSS; CONSTIPATION; DEPRESSION; DIARRHEA; DIET THERAPY; DIZZINESS; DOSE RESPONSE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FRACTURE; HEART PALPITATION; HEART RATE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INSOMNIA; MEMORY; MENTAL DISEASE; MOOD CHANGE; NAUSEA; NONHUMAN; OBESITY; PARESTHESIA; RHINOPHARYNGITIS; SEIZURE; SIDE EFFECT; SKIN MANIFESTATION; SUICIDAL IDEATION; TASTE DISORDER; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 77955576259     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3082398     Document Type: Article

References (65)

1. Global Strategy on Diet, Physical Activity and Health. World Health Organization: Geneva, Switzerland, 2010. Available online: http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/print.html/ (accessed on 12 June 2010).
2. Flegal, K.M.; Graubard, B.I.; Williamson, D.F.; Gail, M.H. Cause specific excess deaths associated with underweight, overweight and obesity. J. Am. Med. Assoc. 2007, 298, 2028-2037.
3. Douketis, J.D.; Macie, C.; Thabane, L.; Williamson, D.F. Systematic review of long-term weight loss studies in obese adults: Clinical significance and applicability to clinical practice. Int. J. Obes. (Lond.) 2005, 29, 1153-1167.
4. Rucker, D.; Padwal, R.; Li, S.K.; Curioni, C.; Lau, D.C.W. Long term pharmacotherapy for obesity and overweight: Updated meta-analysis. Br. Med. J. 2007, 335, 1194-1199.
5. Bray, G.A. Lifestyle and pharmacological approaches to weight loss: Efficacy and safety. J. Clin. Endocrinol. Metab. 2008, 93, S81-S88.
6. Cercato, C.; Roizenblatt, V.A.; Leança, C.C.; Segal, A.; Lopes Filho, A.P.; Mancini, M.C.; Halpern, A. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects. Int. J. Obes. 2009, 33, 857-865.
7. Padwal, R.; Kezouh, A.; Levine, M.; Etminan, M. Long-term persistence with orlistat and sibutramine in a population based cohort. Int. J. Obes. 2007, 31, 1567-1570.
8. Sjöström, L.; Narbro, K.; Sjöström, C.D.; Karason, K Larsson B; Wedel H; Lystig T; Sullivan M; Bouchard C; Carlsson B; Bengtsson C; Dahlgren S; Gummesson A; Jacobson P; Karlsson J; Lindroos AK; Lönroth H; Näslund I; Olbers T; Stenlöf K; Torgerson J; Agren G; Carlsson LM; Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N. Engl. J. Med. 2007, 357, 741-752.
9. U.S. Food and Drug Administration (FDA). Follow-Up to the November 2009 Early Communication about an Ongoing Safety Review of Sibutramine, Marketed as Meridia. Available online: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm198206.htm/. (accessed on 12 June 2010).
10. Halpern, A.; Pepe, R.B.; Monegaglia, A.P.; Beyruti, M.; de Melo, M.E.; Mancini, M.C. Efficacy and tolerability of the association of sibutramine and orlistat for 6 months in overweight and obese patients. J. Obes. 2010, doi:10.1155/2010/602537.
11. Hendricks, E.J.; Rothman, R.B.; Greenway, F.L. How physician obesity specialists use drugs to treat obesity. Obesity (Silver Springs) 2009, 17, 1730-1735.
12. Gadde, K.M.; Allison, D.B. Combination pharmaceutical therapy for obesity. Expert Opin. Pharmacother. 2009, 10, 921-925.
13. Munro, J.F.; MacCuish, A.C.; Wilson, E.M.; Duncan, L.J.P. Comparison of continuous and intermittent anorectic therapy in obesity. Br. Med. J. 1968, 1, 352-354.
14. Truant, A.P.; Olon, L.P.; Cobb, S. Phentermine resin as an adjunct in medical weight reduction: A controlled randomized, double-blind prospective study. Curr. Ther. Res. Clin. Exp. 1972, 14, 726-738.
15. Halford, J.C.G; Harrold, J.A.; Boyland, E.J.; Lawton, C.L.; Blundell, J.E. Serotonergic drugs: Effects on appetite expression and use for the treatment of obesity. Drugs 2007, 67, 27-55.
16. Guy-Grand, B.; Apfelbaum, M.; Crepaldi, G.; Gries, A.; Lefebvre, P.; Turner, P. International trial of long-term dexfenfluramine in obesity. Lancet 1989, II, 1142-1145.
17. Weintraub, M.; Hasday, J.D.; Mushlin, A.I.; Lockwood, D.H. A double-blind clinical trial in weight control: Use of fenfluramine and phentermine alone or in combination. Arch. Intern. Med. 1984, 144, 1143-1148.
18. Connolly, H.M.; Crary, J.L.; McGoon, M.D. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 1997, 337, 581-588.
19. Astrup, A.; Toubro, S.; Christensen, N.; Quaade, F. Pharmacology of thermogenic drugs. Am. J. Clin. Nutr. 1992, 55, 246S-248S.
20. Ioannides-Demos, L.L.; Proietto, J.; McNeil, J.J. Pharmacotherapy for obesity-review article. Drugs 2005, 65, 1391-1418.
21. Astrup, A.; Breum, L.; Toubro, S.; Hein, P.; Quaade, F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine an placebo in obese subjects on an energy restricted diet. A double-blind trial. Int. J. Obes. Relat. Metab. Disord. 1992, 16, 269-277.
22. Shekelle, P.G.; Hardy, M.L.; Morton, S.C.; Maglione, M.; Mojica, M.A.; Suttorp, M.J.; Rhodes, S.L.; Jungvig, L.; Gagné, J. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: A meta-analysis. J. Am. Med. Assoc. 2003, 289, 1537-1545.
23. McBride, B.F.; Karapanos, A.K.; Krudysz, A.; Kluger, J.; Coleman, C.I.; White, C.M. Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine: A randomized controlled trial. J. Am. Med. Assoc. 2004, 291, 216-221.
24. Connoley, I.P.; Liu, Y.L.; Frost I.; Reckless, I.P.; Heal, D.J.; Stock, M.J. Thermogenic effects of sibutramine and its metabolites. Br. J. Pharmacol. 1999, 126, 1487-1495.
25. Mancini, M.C.; Halpern, A. Orlistat in the prevention of diabetes in the obese patient. Vasc. Health Risk Manag. 2008, 4, 325-336.
26. Wadden, T.A.; Berkowits, R.I.; Wonble, L.G. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: A placebo controlled trial. Obes. Res. 2000, 6, 431-437.
27. Kaya, A.; Aydin, N.; Topsever, P.; Filiz, M.; Öztürk, A.; Daǧar, A.; Kilinç, E.; Ekmekcioglu, C. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed. Pharmacother. 2004, 58, 582-587.
28. Sari, R.; Balci, M.K.; Cakir, M.; Altunbas, H.; Karayalcin, U. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr. Res. 2004, 30, 159-167.
29. Bray, G.A. Is new hope on the horizon for obesity? Lancet 2008, 372, 1859-1860.
30. Greenway, F.L.; Bray, G.A. Combination drugs for treating obesity. Curr. Diab. Rep. 2010, 10, 108-115.
31. Sari, R.; Balci, M.K.; Coban, E.; Yazicioglu, G. Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women. Int. J. Obes. Relat. Metab. Disord. 2004, 28, 1059-1063.
32. Knowler, W.C.; Barrett-Connor, E.; Fowler, S.E. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002, 346, 393-403.
33. Contrave and Empatic. Orexigen Therapeutics, Inc. Available on line: http://www.orexigen.com/. (accessed on 16 Mar 2010).
34. Anderson, J.W.; Greenway, F.L.; Fujioka, K. Bupropion SR enhances weight loss: A 48-week double-blind, placebo- controlled trial. Obes. Res. 2002, 10, 633-641.
35. Lee, M.W.; Fujioka, K. Naltrexone for the treatment of obesity: Review and update. Expert Opin. Pharmacother. 2009, 10, 1841-1845.
36. Grill, H.J. Leptin and the systems neuroscience of meal size control. Front Neuroendocrinol. 2010, 31, 61-78.
37. Cummings, D.E.; Overduin J. Gastrointestinal regulation of food intake. J. Clin. Invest. 2007, 117, 13-23.
38. Greenway, F.L.; Whitehouse, M.J.; Guttadauria, M.; Anderson, J.W.; Atkinson, R.L.; Fujioka, K.; Gadde, K.M.; Gupta, A.K.; O'Neil, P.; Schumacher, D.; Smith, D.; Dunayevich, E.; Tollefson, G.D.; Weber, E.; Cowley, M.A. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Springs) 2009, 17, 30-39.
39. Padwal, R. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. Curr. Opin. Investig. Drugs 2009, 10, 1117-1125.
40. Greenway, F.L.; Dunayevich, E.; Tollefson, G.; Erickson, J.; Guttadauria, M.; Fujioka, K.; Cowley, M.A. NB-201 Study Group. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J. Clin. Endocrinol. Metab. 2009, 94, 4898-4906.
41. Oommen, K.J.; Mathews, S. Zonisamide: A new antiepileptic drug. Clin. Neuropharmacol. 1999, 22, 192-200.
42. Gadde, K.M.; Franciscy, D.M.; Wagner, H.R. 2nd; Krishnan K.R. Zonisamide for weight loss in obese adults: A randomized controlled trial. J. Am. Med. Assoc. 2003, 289, 1820-1825.
43. McElroy, S.L.; Kotwal, R.; Guerdjikova, A.I.; Welge, J.A.; Nelson, E.B.; Lake, K.A.; D'alessio, D.A.; Keck, P.E.; Hudson, J.I. Zonisamide in the treatment of binge eating disorder with obesity: A randomized controlled trial. J. Clin. Psychiatry. 2006, 67, 1897-1906.
44. Astrup, A.; Toubro, S. Topiramate: A new potential pharmacological treatment for obesity. Obes. Res. 2004, 12, 167S-173S.
45. Leombruni, P.; Lavagnino, L.; Fassino, S. Treatment of obese patients with binge eating disorder using topiramate: A review. Neuropsychiatr. Dis. Treat. 2009, 5, 385-392.
46. Vivus, Inc. Qnexa Obesity. Available on line: http://www.vivus.com/pipeline/qnexa-obesity/, (accessed on 16 Mar 2010).
47. Woods, S.C.; D'Alessio, D.A. Central Control of Body Weight and Appetite. J. Clin. Endocrinol. Metab. 2008, 93, S37-S50.
48. Ravussin, E.; Smith, S.R.; Mitchell, J.A.; Shringarpure, R.; Shan, K.; Maier, H.; Koda, J.E.; Weyer, C. Enhanced weight loss with pramlintide/metreleptin: An integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009, 17, 1736-1743.
49. Smith, S.R.; Aronne, L.J.; Burns, C.M.; Kesty, N.C.; Halseth, A.E.; Weyer, C. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 2008, 31, 1816-1823.
50. Heymsfield, S.B.; Greenberg, A.S.; Fujioka, K.; Dixon, R.M.; Kushner, R.; Hunt, T.; Lubina, J.A.; Patane, J.; Self, B.; Hunt, P.; McCamish, M. Recombinant leptin for weight loss in obese and lean adults: A randomized, controlled, dose-escalation trial. J. Am. Med. Assoc. 1999, 282, 1568-75.
51. Rosenbaum, M.; Goldsmith, R.; Bloomfield, D.; Magnano, A.; Weimer, L.; Heymsfield, S.; Gallagher, D.; Mayer, L.; Ellen, M.; Leibel, R.L. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J. Clin. Invest. 2005, 115, 3579-3586.
52. Trevaskis, J.L.; Coffey, T.; Cole, R.; Lei, C.; Wittmer, C.; Walsh, B.; Weyer, C.; Koda, J.; Baron, A.D.; Parkes, D.G.; Roth, J.D. Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: Magnitude and mechanisms. Endocrinology 2008, 149, 5679-5687.
53. Aronne, L.J.; Halseth, A.; Burns, C.; Miller, S.; Shen, L.Z. Enhanced weight loss following co-administration of pramlintide with sibutramine or phentermine in obese subjects. Obesity (Silver Spring) 2010, doi: 10.1038/oby.2009.478.
54. Turton, M.D.; O'Shea, D.; Gunn, I.; Beak, S.A.; Edwards, C.M.B.; Meeran, K.; Choi, S.J.; Taylor, G.M.; Heath, M.M.; Lambert, P.D.; Wilding, J.P.H.; Smith D.M.; Ghatei M.A.; Herbert J.; Bloom, S.R. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996, 379, 69-72.
55. Zander, M.; Madsbad, S.; Madsen, J.L.; Holst, J.J. Effect of 6-week course of glucagon-like peptide-1 on glycaemic control, insulin sensivity, and -cell function in type 2 diabetes: A parallel group study. Lancet 2002, 359, 824-830.
56. DeFronzo, R.A.; Ratner, R.E.; Han, J.; Kim, D.D.; Fineman, M.S.; Baron, A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28, 1092-1100.
57. Astrup, A.; Rössner, S.; van Gaal, L.; Rissanen, A. NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study. Lancet 2009, 374, 1606-1616.
58. Adran, T.E.; Ferri, G.L.; Bacarese-Hamilton, A.J.; Fuessl, H.S.; Polak, J.M.; Bloom, S.R. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985, 89, 1070-1077.
59. Batterham, R.L.; Cohen, M.A.; Ellis, S.M.; Le Roux, C.W.; Withers, D.J.; Frost, G.S.; Ghatei, M.A.; Blook, S.R. Inhibition of food intake in obese subjects by peptide YY 3-36. N. Engl. J. Med. 2003, 349, 941-948.
60. Emisphere Technologies, Inc. Emisphere Technologies Reports Encouraging Data from Independent Clinical Study Assessing the Effects of Oral GLP-1 e PYY3-36, Combined with Eligen, June 2009. Available online: http://ir.emisphere.com/releasedetail.cfm?-ReleaseID=385806/. (accessed on 12 June 2010).
61. Turner, E.H.; Loftis, J.M.; Blackwell, A.D. Serotonin a la carte: Supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacol. Ther. 2006, 109, 325-338.
62. Rothman, R.B. Treatment of obesity with "combination" pharmacotherapy. Am. J. Ther. 2009.
63. Jackson, C.W.; Cates, M.; Lorenz, R. Pharmacotherapy of eating disorders, Nutr. Clin. Pract. 2010, 25,143-159.
64. Berkowitz, R.I.; Fabricatore, A.N. Obesity, psychiatric status, and psychiatric medications. Psychiatr. Clin. North Am. 2005, 28, 39-54.
65. Huang, B.C.; Liou, H.H. Sibutramine-induced recurrent seizures. Epilepsy Behav. 2009, 15, 399.